Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2008-04-01
2008-04-01
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001810, C424S001850
Reexamination Certificate
active
07351401
ABSTRACT:
This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
REFERENCES:
patent: 3257204 (1966-06-01), Süs et al.
patent: 4500340 (1985-02-01), Becker et al.
patent: 4540648 (1985-09-01), Scheler
patent: 5935927 (1999-08-01), Vitck et al.
patent: 6034246 (2000-03-01), Stevens et al.
patent: 6696039 (2004-02-01), Kung et al.
patent: 6858633 (2005-02-01), Stevens et al.
patent: 6946116 (2005-09-01), Kung et al.
patent: 7270800 (2007-09-01), Klunk et al.
patent: 2003/0236391 (2003-12-01), Klunk et al.
patent: 0 081 141 (1981-12-01), None
patent: 0 118 086 (1983-03-01), None
patent: 0 287 909 (1988-10-01), None
patent: WO 95/06469 (1995-03-01), None
patent: WO 97/26919 (1997-07-01), None
patent: WO 98/17267 (1998-04-01), None
patent: WO 01/14354 (2001-03-01), None
patent: WO 02/16333 (2002-02-01), None
patent: WO 02/085903 (2002-10-01), None
Shi et al., “Antitumor Benzothiazoles, 3. Synthesis of 2-(4-Aminophenyl)benzothiazoles and Evaluation of Their Activities against Breast Cancer Cell Lines in Vitro and in Vivo”,J. Med. Chem., 1996, pp. 3375-3384, vol. 39, The American Chemical Society.
Cuadro et al., “Styryl and Azastyryl 1,3-Benzazoles with Antihelmitic Activity”,II Farmaco, 1992, pp. 477-488, vol. 47, No. 4.
Fokken et al., “Beitrag zur Darstellung von Verbindungen mit Amidino- bzw. Amidoximstruktur”,Pharmazie, 1977, pp. 566-569, Pharmazie 32, H.10 (19).
Grozinger et al., Heterocyclic ethenyloxanilates as orally active antiallergic agents,Eur. J. Med. Chem. Chim. Ther., 1985, pp. 487-491, vol. 20, No. 6.
Dryanska, “α-Hydroxybenzylation and Benzylidenation of the Methyl Group in 2-Methyl-1,3-benzoxazole and 2-Methyl-1,3-benzothiazole” Communications, 1976, pp. 37-38.
Vaz et al., “6-Substituted 2-(p-aminostyryl)benzothiazole derivatives”,Indian J. Chem., 1976, Sect. B, pp. 709-711, vol. 14B, No. 9.
Bogert et al., “Researches on Thiazoles, XVII. An Investigation of the Connection Between Constitution and Color in the Thioflavine Group”, Collection of Czechoslovak Chemical Communications, 1931, pp. 480-498, vol. 3, The Chemical Laboratories.
Martvon et al., “2-Phenyl-6-Benzothiazolyl Isothiocyanates”,Collection Czechoslov, Chem. Commun.1974, pp. 1356-1365, vol. 39, No. 5.
Klunk et al., “Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain”,Life Sciences, 2001, pp. 1471-1484, vol. 69, No. 13, Elsevier Pub.
Wang et al., “Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of beta-amyloid deposits in aging and Alzheimer's disease”,Journal of Labelled Compounds and Radiopharmaceuticals, 2001, pp. S239-S241, vol. 44, No. Supp. 1.
Mathis et al., “Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease”,Journal of Labelled Compounds and Radiopharmaceuticals, 2001, pp. S26-S28, vol. 44, No. Supp. 1.
Zhuang et al., “Radioiodianted Styrylbenzenes and Thioflavins as Probes for Amyloid Aggregates”,Journal of Medicinal Chemistry, vol. 44, No. 12, 2001, pp. 1905-1914.
International Search Report, 2004.
Yanming Wang et al., “Synthesis and Evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for In Vivo Quantitation of Amyloid Deposits in Alzheimer's Disease”, Journal of Molecular Neuroscience, vol. 19, 2002, pp. 11-14.
Chester A. Mathis et al., “A Lipophilic Thioflavin-T Derivative for Positron Emission Tomorgraphy (PET) Imaging of Amyloid in Brain”, Bioorganic & Medicinal Chemistry Letters, 12 (2002), pp. 295-298.
Chester A. Mathis et al., “Synthesis and Evaluation of11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents”, J. Med. Chem., 2003, 46, pp. 2740-2754.
Klunk William E.
Mathis, Jr. Chester A.
Wang Yanming
Foley & Lardner LLP
Jones Dameron L.
University of Pittsburgh
LandOfFree
Thioflavin derivatives for use in the antemortem diagnosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thioflavin derivatives for use in the antemortem diagnosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thioflavin derivatives for use in the antemortem diagnosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757417